What changed: Brain metastases (secondary brain tumours)
Every dated change on the records linked to Brain metastases (secondary brain tumours), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 2
April 2020 · 1
2020 · 5
- 2020ApprovalTucatinibTucatinib approved in US
HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine
- 2020Trial resultCROWNCROWN reported
5-year PFS 60% vs 8%, HR 0.
- 2020Trial resultNRG CC001NRG CC001 reported
Cognitive failure hazard ratio 0.
- 2020MilestoneTucatinibHER2CLIMB: tucatinib triplet benefits patients with HER2-positive brain metastases
A milestone in how this cancer is treated.
- 2020MilestoneNRG CC001NRG CC001: hippocampal-avoidance whole-brain radiotherapy with memantine preserves cognition
A milestone in how this cancer is treated.
2019 · 1
2018 · 2
2017 · 1
2016 · 4
- 2016Trial resultAlliance N0574 (NCCTG N0574)Alliance N0574 (NCCTG N0574) reported
Cognitive deterioration at 3 months 63.
- 2016Trial resultQUARTZQUARTZ reported
Quality-adjusted life-years 46.
- 2016MilestoneAlliance N0574 (NCCTG N0574)Alliance N0574: radiosurgery alone preserves cognition
Brown and colleagues (JAMA): cognitive deterioration at three months in 63.5 percent with radiosurgery alone against 91.7 percent with added whole-brain radiotherapy; no survival difference.
- 2016MilestoneQUARTZQUARTZ: no quality-adjusted survival gain from whole-brain radiotherapy in poor-prognosis lung cancer
A milestone in how this cancer is treated.